FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3100871656> ?p ?o ?g. }

• W3100871656 abstract "Background TAK-573, a humanized, anti-CD38, IgG4, monoclonal antibody genetically fused to two attenuated IFNα2b molecules, was designed for targeted delivery of attenuated IFNα2b to CD38 expressing (CD38+) cells, utilizing a unique epitope of CD38 that does not compete with current anti-CD38 therapies. Preclinical evaluation of TAK-573 confirmed activation of type I IFN signaling in CD38+ cells inducing direct anti-proliferative effects on multiple myeloma (MM) cells and direct and indirect immune cell activation. Here we provide the preliminary analyses of the pharmacodynamic data currently available from the ongoing Ph I/II TAK-573-1501 clinical study in patients with relapsed/refractory MM ( NCT03215030 ). Methods Peripheral blood (PB) and bone marrow (BM) aspirates were collected from patients at pre- and post-dose time points for exploratory biomarker analyses. CD38 receptor occupancy (RO) and receptor density (RD) were determined using a 9-color flow cytometry assay. Whole transcriptome sequencing of bulk RNA was performed and analyzed to assess the type I IFN gene signature. Serum samples were analyzed using Olink’s Proximity Extension Assay Immuno-Oncology panel to measure changes in cytokine levels. Mass cytometry-based immunophenotyping was utilized to characterize changes in immune cell prevalence and activation status of cryopreserved cells. Results Administration of TAK-573 resulted in a dose dependent increase in CD38 RO of PB-derived immune cells with saturation detected 4 hours after the end of infusion (EOI) at doses ≥ 0.2 mg/kg. The duration of saturation was dose dependent with doses ≥ 0.75 mg/kg saturating CD38 RO through 24 hours. All dose levels tested resulted in increases in the type I IFN gene signature at 24 hours. Consistent with CD38 being an IFN stimulated gene, TAK-573 treatment resulted in CD38 RD increases most notably on NK cells, but also on other CD38+ cells including MM cells. Circulating levels of IFN-associated cytokines were also elevated, with maximal induction 4 hours after the EOI. CD8+ T-cells in BM showed increased CD69 expression in 7 of 9 patients analyzed, 3 of whom also showed increases in both IFNγ and granzyme B positivity suggesting TAK-573 treatment results in increased BM cytolytic CD8+ T-cells, in a subset of patients. Abstract 357 Figure 1 Proposed Mechanism of Action of TAK-573 Conclusions These preliminary biomarker data indicate that TAK-573 is a pharmacologically active molecule that mediates its effect through IFNAR pathway modulation. Additional data are being collected to further refine the mechanism of action (Image 1), which will inform the recommended phase 2 dose and optimal schedule of administration for the development of TAK-573. Trial Registration ClinicalTrials. gov: NCT03215030 Ethics Approval The TAK-573-1501 study is approved by WIRB-Copernicus Group, University of Nebraska Medical Center, Dana Farber Cancer Institute and Advarra IRBs." @default.
• W3100871656 created "2020-11-23" @default.
• W3100871656 creator A5001458693 @default.
• W3100871656 creator A5015775019 @default.
• W3100871656 creator A5022352652 @default.
• W3100871656 creator A5025211692 @default.
• W3100871656 creator A5030803409 @default.
• W3100871656 creator A5039066645 @default.
• W3100871656 creator A5041822106 @default.
• W3100871656 creator A5057121947 @default.
• W3100871656 creator A5065131494 @default.
• W3100871656 creator A5068517310 @default.
• W3100871656 creator A5073759779 @default.
• W3100871656 creator A5080284206 @default.
• W3100871656 date "2020-11-01" @default.
• W3100871656 modified "2023-09-27" @default.
• W3100871656 title "357 TAK-573, an anti-CD38–attenuated interferon alpha (IFNα) fusion protein (Attenukine™), has demonstrated IFNα receptor (IFNAR) pathway modulation in patients with relapsed/refractory multiple myeloma" @default.
• W3100871656 doi "https://doi.org/10.1136/jitc-2020-sitc2020.0357" @default.
• W3100871656 hasPublicationYear "2020" @default.
• W3100871656 type Work @default.
• W3100871656 sameAs 3100871656 @default.
• W3100871656 citedByCount "3" @default.
• W3100871656 countsByYear W31008716562021 @default.
• W3100871656 countsByYear W31008716562022 @default.
• W3100871656 crossrefType "proceedings-article" @default.
• W3100871656 hasAuthorship W3100871656A5001458693 @default.
• W3100871656 hasAuthorship W3100871656A5015775019 @default.
• W3100871656 hasAuthorship W3100871656A5022352652 @default.
• W3100871656 hasAuthorship W3100871656A5025211692 @default.
• W3100871656 hasAuthorship W3100871656A5030803409 @default.
• W3100871656 hasAuthorship W3100871656A5039066645 @default.
• W3100871656 hasAuthorship W3100871656A5041822106 @default.
• W3100871656 hasAuthorship W3100871656A5057121947 @default.
• W3100871656 hasAuthorship W3100871656A5065131494 @default.
• W3100871656 hasAuthorship W3100871656A5068517310 @default.
• W3100871656 hasAuthorship W3100871656A5073759779 @default.
• W3100871656 hasAuthorship W3100871656A5080284206 @default.
• W3100871656 hasConcept C10205521 @default.
• W3100871656 hasConcept C104317684 @default.
• W3100871656 hasConcept C121332964 @default.
• W3100871656 hasConcept C123079801 @default.
• W3100871656 hasConcept C123894998 @default.
• W3100871656 hasConcept C126322002 @default.
• W3100871656 hasConcept C142424586 @default.
• W3100871656 hasConcept C159110408 @default.
• W3100871656 hasConcept C159912055 @default.
• W3100871656 hasConcept C170493617 @default.
• W3100871656 hasConcept C185592680 @default.
• W3100871656 hasConcept C203014093 @default.
• W3100871656 hasConcept C24890656 @default.
• W3100871656 hasConcept C2775944032 @default.
• W3100871656 hasConcept C2776178377 @default.
• W3100871656 hasConcept C2776364478 @default.
• W3100871656 hasConcept C28328180 @default.
• W3100871656 hasConcept C2909179924 @default.
• W3100871656 hasConcept C40767141 @default.
• W3100871656 hasConcept C49453240 @default.
• W3100871656 hasConcept C502942594 @default.
• W3100871656 hasConcept C55493867 @default.
• W3100871656 hasConcept C64943373 @default.
• W3100871656 hasConcept C71924100 @default.
• W3100871656 hasConcept C86803240 @default.
• W3100871656 hasConcept C87355193 @default.
• W3100871656 hasConcept C95444343 @default.
• W3100871656 hasConcept C98274493 @default.
• W3100871656 hasConceptScore W3100871656C10205521 @default.
• W3100871656 hasConceptScore W3100871656C104317684 @default.
• W3100871656 hasConceptScore W3100871656C121332964 @default.
• W3100871656 hasConceptScore W3100871656C123079801 @default.
• W3100871656 hasConceptScore W3100871656C123894998 @default.
• W3100871656 hasConceptScore W3100871656C126322002 @default.
• W3100871656 hasConceptScore W3100871656C142424586 @default.
• W3100871656 hasConceptScore W3100871656C159110408 @default.
• W3100871656 hasConceptScore W3100871656C159912055 @default.
• W3100871656 hasConceptScore W3100871656C170493617 @default.
• W3100871656 hasConceptScore W3100871656C185592680 @default.
• W3100871656 hasConceptScore W3100871656C203014093 @default.
• W3100871656 hasConceptScore W3100871656C24890656 @default.
• W3100871656 hasConceptScore W3100871656C2775944032 @default.
• W3100871656 hasConceptScore W3100871656C2776178377 @default.
• W3100871656 hasConceptScore W3100871656C2776364478 @default.
• W3100871656 hasConceptScore W3100871656C28328180 @default.
• W3100871656 hasConceptScore W3100871656C2909179924 @default.
• W3100871656 hasConceptScore W3100871656C40767141 @default.
• W3100871656 hasConceptScore W3100871656C49453240 @default.
• W3100871656 hasConceptScore W3100871656C502942594 @default.
• W3100871656 hasConceptScore W3100871656C55493867 @default.
• W3100871656 hasConceptScore W3100871656C64943373 @default.
• W3100871656 hasConceptScore W3100871656C71924100 @default.
• W3100871656 hasConceptScore W3100871656C86803240 @default.
• W3100871656 hasConceptScore W3100871656C87355193 @default.
• W3100871656 hasConceptScore W3100871656C95444343 @default.
• W3100871656 hasConceptScore W3100871656C98274493 @default.
• W3100871656 hasLocation W31008716561 @default.
• W3100871656 hasOpenAccess W3100871656 @default.
• W3100871656 hasPrimaryLocation W31008716561 @default.
• W3100871656 hasRelatedWork W1964243029 @default.
• W3100871656 hasRelatedWork W1976949247 @default.
• W3100871656 hasRelatedWork W2046045290 @default.
• W3100871656 hasRelatedWork W2051044840 @default.

• next